Meningioma and levonorgestrel morning-after pill

Korhonen K, Auvinen A, Lyytinen H, Ylikorkala O, Pukkala E. A nationwide cohort study on the incidence of meningioma in women using postmenopausal hormone therapy in Finland. Am J Epidemiol. 2012;175(4):309-314.

Fischer F (1931). Z Augenheilk Z, 75, 343. (1935). Ibid., 85, 88.

Michelsen JJ, New PF. Brain tumour and pregnancy. J Neurol Neurosurg Psychiatry. 1969;32(4):305-307.

Poisson M, Magdelenat H, Foncin JF, et al. Récepteurs d’oestrogènes et de progestérone dans les méningiomes. Etude de 22 cas [Estrogen and progestin receptors in meningiomas: a study in 22 cases (author’s transl)]. Rev Neurol (Paris). 1980;136(3):193-203.

Froehlich S, Dali-Youcef N, Boyer P, et al. Does cyproterone acetate promote multiple meningiomas? Endocrine Abstracts.2008;16:

Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J Neurooncol. 2010;99(3):307-314.

Miyagishima DF, Moliterno J, Claus E, Günel M. Hormone therapies in meningioma-where are we? J Neurooncol. 2023;161(2):297-308.

Plese JP, Martins VR, Lopes MT, Brentani MM. Steroid receptors in meningiomas. Arq Neuropsiquiatr. 1985;43(4):365-371.

Carroll RS, Glowacka D, Dashner K, Black PM. Progesterone receptor expression in meningiomas. Cancer Res. 1993;53(6):1312-1316.

Ji Y, Rankin C, Grunberg S, et al. Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol. 2015;33(34):4093-4098.

Agence nationale de Sécurité du medicament et des produits de santé. Comité Scientifique Temporaire «Macroprogestatifs et risque de méningiome». 8 june Available at: https://ansm.sante.fr/uploads/2020/11/19/20201105-cr-cst-meningiome-progestatifs-2.pdf

Levonorgestrel: hormone. Britannica. Oct 14, 2024. Available at: https://www.britannica.com/science/levonorgestrel

European Medicines Agency. Science Medicines Health.Medicines containing nomegestrol or chlormadinone: PRAC recommends new measures to minimise risk of meningioma. July 2022. Available at: https://www.ema.europa.eu/en/news/medicines-containing-nomegestrol-or-chlormadinone-prac-recommends-new-measures-minimise-risk-meningioma

European Medicines Agency. Science Medicines Health. 13 february 2020. Cyproterone-containing medicinal products – referral. Available at: https://www.ema.europa.eu/en/medicines/human/referrals/cyproterone-containing-medicinal-products?

Peyre M, Gaillard S, de Marcellus C, et al. Progestin-associated shift of meningioma mutational landscape. Ann Oncol. 2018;29(3):681-686.

Graillon T, Boissonneau S, Appay R, et al. Meningiomas in patients with long-term exposition to progestins: Characteristics and outcome. Neurochirurgie. 2021;67(6):556-563.

Huang H, Buhl R, Hugo HH, Mehdorn HM. Clinical and histological features of multiple meningiomas compared with solitary meningiomas. Neurol Res. 2005;27(3):324-332.

Planty-Bonjour A, Terrier LM, Cognacq G, et al. Bilateral spheno-orbital meningiomas: surgical management, progression, and recurrence. J Neurosurg. 2024;141(3):702-710.

Malueka RG, Hartanto RA, Setyawan NH, et al. Association of Hormonal Contraception with Meningioma Location in Indonesian Patients. Asian Pac J Cancer Prev. 2022 Mar 1;23(3):1047-1051.

Supartoto A, Mahayana IT, Christine RN, et al. Exposure to exogenous female sex hormones is associated with increased risk oforbito-cranial meningioma in females: a case-control study. Int J Ophtalmic Pathol. 2016;5(3):1-6.

Apra C, Roblot P, Alkhayri A, Le Guérinel C, Polivka M, Chauvet D. Female gender and exogenous progesterone exposition as risk factors for spheno-orbital meningiomas. J Neurooncol. 2020;149(1):95-101.

Nagahama A, Goto T, Nagm A, et al. Spheno-Orbital Meningioma: Surgical Outcomes and Management of Recurrence. World Neurosurg. 2019;126:e679-e687.

Borovich B, Doron Y, Braun J, et al. The incidence of multiple meningiomas–do solitary meningiomas exist? Acta Neurochir (Wien). 1988;90(1-2):15-22.

Wahab M, Al-Azzawi F. Meningioma and hormonal influences. Climacteric. 2003;6(4):285-292.

Vadivelu S, Schulder M. Intracranial Meningiomas: Role of Exogenous Hormones. In Tumors of the Central Nervous System, Volume 7: Meningiomas and Schwannomas. Dordrecht: Springer Netherlands. 2012. pp. 29-38.

Hoisnard L, Laanani M, Passeri T, et al. Risk of intracranial meningioma with three potent progestogens: A population-based case-control study. Eur J Neurol. 2022;29(9):2801-2809.

Risque de méningiome et progestatifs: l’ANSM réunit un nouveau comité d’experts patients et professionnels de santé. ANSM. 20 Jan 2023. Available at : https://ansm.sante.fr/actualites/risque-de-meningiome-et-progestatifs-lansm-reunit-un-nouveau-comite-dexperts-patients-et-professionnels-de-sante

Roland N, Neumann A, Hoisnard L, et al. Use of progestogens and the risk of intracranial meningioma: national case-control study. BMJ. 2024;384:e078078.

Expert reaction to study finding an association between prolonged use of progestogen hormones and brain tumour risk. Science Media Center. 27 March 2024. Available at: https://www.sciencemediacentre.org/expert-reaction-to-study-finding-an-association-between-prolonged-use-of-progestogen-hormones-and-brain-tumour-risk/

Risque de méningiome et progestatifs : recommandations générales pour limiter ce risque ANSM. 2 March 2023. Available at: https://ansm.sante.fr/actualites/risque-de-meningiome-et-progestatifs-recommandations-generales-pour-limiter-ce-risque

Resume des caracteristiques du produit. 2021. Available at: https://www.pi.bayer.com/sites/g/files/vrxlpx33726/files/2021-12/210921-Jaydess-spc-fr-clean.pdf

Piper JG, Follett KA, Fantin A. Sphenoid wing meningioma progression after placement of a subcutaneous progesterone agonist contraceptive implant. Neurosurgery. 1994;34(4):723-725.

Isabelle W, Rusu S, Remmelink M, Foucart A, Compere C. Multiple Primary Pulmonary Meningiomas: Case Report and Literature Review. Ann Case Report. 2023;8:

Wigertz A, Lönn S, Mathiesen T, Ahlbom A, Hall P, Feychting M; Swedish Interphone Study Group. Risk of brain tumors associated with exposure to exogenous female sex hormones. Am J Epidemiol. 2006;164(7):629-636.

Risque de méningiome et progestatifs. Centre Belge D’information Pharmacothérapeutique. Available at: https://www.cbip.be/fr/risque-de-meningiome-et-progestatifs/

Progestatifs et risque de méningiome : renforcement des conditions de prescription et de délivrance de Depo Provera 150 mg/3 mL et Colprone 5 mg. ANSM. 28 June 2024. Available at: https://ansm.sante.fr/actualites/progestatifs-et-risque-de-meningiome-renforcement-des-conditions-de-prescription-et-de-delivrance-de-depo-provera-150-mg-3-ml-et-colprone-5-mg

Contraception: pourquoi les femmes délaissent la pilule? IFOP group. 26 September 2018. Available at: https://www.ifop.com/publication/contraception-pourquoi-les-femmes-delaissent-la-pilule/

What’s the Plan B morning-after pill? Planned parenthood. Available at: https://www.plannedparenthood.org/learn/morning-after-pill-emergency-contraception/whats-plan-b-morning-after-pill

Birth control. From the FDA Office of Women’s Health. Available at: https://www.fda.gov/consumers/womens-health-topics/birth-control

Medical Treatments for Endometriosis. Brigham and women’s Hospital. Available at: https://www.brighamandwomens.org/obgyn/infertility-reproductive-surgery/endometriosis/medical-treatment-for-endometriosis

Nomegestrol acetate. Steroids progestogens. Available at: https://drugcentral.org/drugcard/1957

Custer B, Longstreth WT Jr, Phillips LE, Koepsell TD, Van Belle G. Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study. BMC Cancer. 2006;6:152.

Raudrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs. 2003;63(5):463-492.

Li Q, Coulson H, Klaassen Z, et al. Emerging association between androgen deprivation therapy and male meningioma: significant expression of luteinizing hormone-releasing hormone receptor in male meningioma. Prostate Cancer Prostatic Dis. 2013;16(4):387-390.

Portet S, Banor T, Bousquet J, et al. New Insights into Expression of Hormonal Receptors by Meningiomas. World Neurosurg. 2020;140:e87-e96.

Agopiantz M, Carnot M, Denis C, Martin E, Gauchotte G. Hormone Receptor Expression in Meningiomas: A Systematic Review. Cancers (Basel). 2023;15(3):980.

Harris E. Use of Progestogen Tied to Higher Chance of Benign Brain Tumor. JAMA. 2024;331(18):1525-1526.

Bailey DS, John K, Daggubati LC, Zacharia BE. Regression of Multiple Intracranial Meningiomas With Cessation of Progesterone Agonist Therapy: A Case Report. Cureus. 2024;16(1):e52479.

Cornu E, Reuter G, Pintiaux A, et al. Meningioma under progestin treatment: what attitude to adopt? Maturitas. 2023;173:95. Abstract ID: 220. Available at: https://orbi.uliege.be/bitstream/2268/305965/1/1-s2.0-S0378512223002803-main.pdf

GHU Paris. Méningomes et médicaments dérivés de la progestérone. Livret d’infomration. Available at: https://www.ghu-paris.fr/sites/default/files/media/downloads/mmdp-230906-1.pdf

Mowszowicz I, Bieber DE, Chung KW, Bullock LP, Bardin CW. Synandrogenic and antiandrogenic effect of progestins: comparison with nonprogestational antiandrogens. Endocrinology. 1974;95(6):1589-1599.